# AI-Assisted Benefit-Risk Assessment
Every regulatory decision about a drug ultimately comes down to benefit-risk: do the therapeutic benefits outweigh the safety risks for the intended patient population? This assessment is not a one-time calculation — it is a continuous process that evolves from pre-approval through the entire product lifecycle.
Structured Benefit-Risk Frameworks
The FDA and EMA have endorsed structured approaches to benefit-risk assessment, including the Benefit-Risk Action Team (BRAT) framework and the PrOACT-URL method. These frameworks require:
- 1.Decision context — What is the therapeutic need? What are the alternatives?
- 2.Outcome identification — What are the key benefits (efficacy endpoints) and risks (safety outcomes)?
- 3.Data source identification — What evidence informs each outcome?
- 4.Evidence synthesis — What does the totality of data show for each outcome?
- 5.Assessment and trade-offs — How do benefits and risks compare across the patient population?
Unlock this lesson
Upgrade to Pro to access the full content
What you'll learn:
- Use AI to structure quantitative benefit-risk frameworks for regulatory submissions and lifecycle management
- Apply AI to synthesize evidence from multiple sources into integrated benefit-risk summaries
- Build prompts that generate balanced benefit-risk narratives for different stakeholder audiences